These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

743 related items for PubMed ID: 24089054

  • 1. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
    Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, Tun R, Chang YC, Tsai GE.
    JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
    [Abstract] [Full Text] [Related]

  • 2. Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Lin CH, Lin CH, Chang YC, Huang YJ, Chen PW, Yang HT, Lane HY.
    Biol Psychiatry; 2018 Sep 15; 84(6):422-432. PubMed ID: 29397899
    [Abstract] [Full Text] [Related]

  • 3. Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial.
    Lin CH, Chen PK, Chang YC, Chuo LJ, Chen YS, Tsai GE, Lane HY.
    Biol Psychiatry; 2014 May 01; 75(9):678-85. PubMed ID: 24074637
    [Abstract] [Full Text] [Related]

  • 4. Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.
    Lin CY, Liang SY, Chang YC, Ting SY, Kao CL, Wu YH, Tsai GE, Lane HY.
    World J Biol Psychiatry; 2017 Aug 01; 18(5):357-368. PubMed ID: 26691576
    [Abstract] [Full Text] [Related]

  • 5. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D, Fernandes BS, Berk M, Dodd S, Medeiros DW, Pedrini M, Kunz M, Gomes FA, Giglio LF, Lobato MI, Belmonte-de-Abreu PS, Gama CS.
    J Clin Psychiatry; 2009 Oct 01; 70(10):1416-23. PubMed ID: 19906345
    [Abstract] [Full Text] [Related]

  • 6. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
    Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE.
    Arch Gen Psychiatry; 2005 Nov 01; 62(11):1196-204. PubMed ID: 16275807
    [Abstract] [Full Text] [Related]

  • 7. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
    Weiser M, Heresco-Levy U, Davidson M, Javitt DC, Werbeloff N, Gershon AA, Abramovich Y, Amital D, Doron A, Konas S, Levkovitz Y, Liba D, Teitelbaum A, Mashiach M, Zimmerman Y.
    J Clin Psychiatry; 2012 Jun 01; 73(6):e728-34. PubMed ID: 22795211
    [Abstract] [Full Text] [Related]

  • 8. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia.
    Lieberman JA, Papadakis K, Csernansky J, Litman R, Volavka J, Jia XD, Gage A, MEM-MD-29 Study Group.
    Neuropsychopharmacology; 2009 Apr 01; 34(5):1322-9. PubMed ID: 19005465
    [Abstract] [Full Text] [Related]

  • 9. Effect of Sodium Benzoate vs Placebo Among Individuals With Early Psychosis: A Randomized Clinical Trial.
    Scott JG, Baker A, Lim CCW, Foley S, Dark F, Gordon A, Ward D, Richardson D, Bruxner G, Beckmann KM, Hatherill S, Stathis S, Dixon K, Ryan AE, McWhinney BC, Ungerer JPJ, Berk M, Dean OM, Saha S, McGrath J.
    JAMA Netw Open; 2020 Nov 02; 3(11):e2024335. PubMed ID: 33170261
    [Abstract] [Full Text] [Related]

  • 10. Impact of dietary benzoic acid on treatment response in schizophrenia.
    Glue P, Gale C, Parnell W.
    JAMA Psychiatry; 2014 Nov 02; 71(11):1298-9. PubMed ID: 25372189
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.
    Keefe RS, Malhotra AK, Meltzer HY, Kane JM, Buchanan RW, Murthy A, Sovel M, Li C, Goldman R.
    Neuropsychopharmacology; 2008 May 02; 33(6):1217-28. PubMed ID: 17625502
    [Abstract] [Full Text] [Related]

  • 12. Impact of dietary benzoic acid on treatment response in schizophrenia--reply.
    Tsai GE.
    JAMA Psychiatry; 2014 Nov 02; 71(11):1299. PubMed ID: 25372191
    [No Abstract] [Full Text] [Related]

  • 13. Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.
    Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M.
    J Clin Psychiatry; 2012 Sep 02; 73(9):e1168-74. PubMed ID: 23059159
    [Abstract] [Full Text] [Related]

  • 14. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
    Lerner V, Miodownik C, Gibel A, Sirota P, Bush I, Elliot H, Benatov R, Ritsner MS.
    J Clin Psychiatry; 2013 Dec 02; 74(12):1224-32. PubMed ID: 24434091
    [Abstract] [Full Text] [Related]

  • 15. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
    Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT.
    Am J Psychiatry; 2007 Oct 02; 164(10):1593-602. PubMed ID: 17898352
    [Abstract] [Full Text] [Related]

  • 16. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial.
    Liu F, Guo X, Wu R, Ou J, Zheng Y, Zhang B, Xie L, Zhang L, Yang L, Yang S, Yang J, Ruan Y, Zeng Y, Xu X, Zhao J.
    Schizophr Res; 2014 Mar 02; 153(1-3):169-76. PubMed ID: 24503176
    [Abstract] [Full Text] [Related]

  • 17. D-alanine added to antipsychotics for the treatment of schizophrenia.
    Tsai GE, Yang P, Chang YC, Chong MY.
    Biol Psychiatry; 2006 Feb 01; 59(3):230-4. PubMed ID: 16154544
    [Abstract] [Full Text] [Related]

  • 18. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
    Lee SW, Lee JG, Lee BJ, Kim YH.
    Int Clin Psychopharmacol; 2007 Mar 01; 22(2):63-8. PubMed ID: 17293705
    [Abstract] [Full Text] [Related]

  • 19. The efficacy of sodium benzoate as an adjunctive treatment in early psychosis - CADENCE-BZ: study protocol for a randomized controlled trial.
    Ryan A, Baker A, Dark F, Foley S, Gordon A, Hatherill S, Stathis S, Saha S, Bruxner G, Beckman M, Richardson D, Berk M, Dean O, McGrath J, Group CW, Scott J.
    Trials; 2017 Apr 07; 18(1):165. PubMed ID: 28388932
    [Abstract] [Full Text] [Related]

  • 20. The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial.
    Schoemaker JH, Jansen WT, Schipper J, Szegedi A.
    J Clin Psychopharmacol; 2014 Apr 07; 34(2):190-8. PubMed ID: 24525661
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.